RBC Capital Initiates Coverage On Solid Biosciences with Outperform Rating, Announces Price Target of $18
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsInitiationPrice Target
RBC Capital analyst Luca Issi initiates coverage on Solid Biosciences (NASDAQ:SLDB) with a Outperform rating and announces Price Target of $18.
RBC Capital analyst Luca Issi initiates coverage on Solid Biosciences (NASDAQ:SLDB) with a Outperform rating and announces Price Target of $18.